Amylyx Pharmaceuticals, Inc. (AMLX) News
Follow Amylyx Pharmaceuticals, Inc. (AMLX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 19 public stories across 13 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Amylyx Pharmaceuticals Reports Quarterly Results
Amylyx Pharmaceuticals reported results for the quarter ended September 30; the available report does not specify the figures.
EQUITY | Nov 05, 2026, 03:17 PM UTC
M
Amylyx Pharmaceuticals’ Q3 Net Loss Widens
Amylyx Pharmaceuticals reported a wider net loss for the third quarter.
EQUITY | Nov 05, 2026, 02:25 PM UTC
M
Amylyx posts Q3 loss of $0.38 per share vs. $0.37 estimate
EQUITY | Nov 05, 2026, 12:21 PM UTC
M
Amylyx Pharmaceuticals Reports $45.5M Third-Quarter Loss
EQUITY | Nov 05, 2026, 12:09 PM UTC
M
Amylyx Reports Third-Quarter 2026 Financial Results
Amylyx also reported positive topline results from its Phase 3 LUCIDITY trial of avexitide; the body text is truncated.
EQUITY | Nov 05, 2026, 12:06 PM UTC
M
Amylyx to Report Third-Quarter 2026 Results on November 5
Amylyx Pharmaceuticals says it will report third-quarter 2026 financial results on November 5, 2026.
EQUITY | Nov 02, 2026, 02:01 PM UTC
H
Amylyx Pharma Q2 2026 Earnings Call Transcript
Amylyx Pharma (NASDAQ: AMLX ) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you APIs. For real-time access to our entire catal
LIVE | Oct 05, 2026, 11:25 AM UTC
L
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will present at the Stifel 2026 Virtual Cardiometabolic Forum. The fireside chat will take place on Wednesday, Septe
NEWS | Sep 23, 2026, 01:00 PM UTC
L
Amylyx Pharmaceuticals Insiders Sold Shares Worth Over $1.9M
Justin B. Klee, a director and Co-Chief Executive Officer, sold common stock in automatic transactions to cover tax withholding on vested performance stock units at weighted average sale prices of $32.1293 for one block
EQUITY | Sep 14, 2026, 08:01 PM UTC
M
Amylyx signs avexitide supply deals with Bachem and Polypeptide
Amylyx Pharmaceuticals entered two non-exclusive agreements for long-term avexitide commercial supply. It signed a five-year Manufacturing and Supply Agreement with Bachem starting in 2028 and a separate agreement with P
EQUITY | Sep 08, 2026, 09:03 PM UTC
L
Amylyx Pharmaceuticals maintained at Buy by Guggenheim
Guggenheim maintained its Buy rating on Amylyx Pharmaceuticals.
EQUITY | Aug 27, 2026, 01:55 PM UTC
M
AMLX, EDSA, QNBC price secondary share offerings
AMLX, EDSA and QNBC are among the names in a set of deals priced today, with AMLX pricing 14.1M shares at $35.50, EDSA 3.87M shares at $5.50 and QNBC 1.07M shares at $43.00.
MNA | Aug 20, 2026, 12:28 PM UTC
M
ANDG and AMLX secondary deals set to price today
ANDG will price a 4.28M share secondary offering today with price TBD, while AMLX has a $350M secondary deal announced last night with shares and pricing TBD.
MNA | Aug 19, 2026, 12:54 PM UTC
L
Guggenheim raises AMLX price target to $55, keeps Buy
Guggenheim raises its AMLX price target from $40 to $55 and maintains a Buy rating, with no catalyst supplied in the alert.
EQUITY | Aug 19, 2026, 12:32 PM UTC
H
Amylyx Pharmaceuticals proposes $350.0M common stock offering
Amylyx Pharmaceuticals (AMLX) announces a proposed $350.0M public offering of common stock, with proceeds to fund avexitide pre-commercial activities, R&D, and general corporate purposes.
EQUITY | Aug 18, 2026, 08:01 PM UTC
H
AMLX jumps on Phase 3 LUCIDITY avexitide topline results
ALXN-backed ally?—No: AMLX is up about 29% after positive topline results from the Phase 3 LUCIDITY clinical trial of avexitide, while HAE and BBWI also post gains and HD adds a 2% earnings move.
EARNINGS | Aug 18, 2026, 12:20 PM UTC
L
Mizuho raises Amylyx target to $30, keeps Outperform
Mizuho analyst Graig Suvannavejh raised Amylyx's price target to $30 from $24 and kept an Outperform rating after the Q2 report, citing updated launch pricing assumptions for avexitide.
EQUITY | Aug 17, 2026, 12:36 PM UTC
M
AMLX: Guggenheim Raises Target
Guggenheim analyst Seamus Fernandez maintains Buy on Amylyx Pharmaceuticals and raises the price target to $40
EQUITY | Jun 25, 2026, 02:12 PM UTC
M
AMLX Presents ALS Trial Data
Amylyx Pharmaceuticals presents data from first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 in ALS at ENCALS 2026
EQUITY | Jun 23, 2026, 11:00 AM UTC